期刊
BIOCHEMICAL ENGINEERING JOURNAL
卷 135, 期 -, 页码 11-21出版社
ELSEVIER
DOI: 10.1016/j.bej.2017.11.005
关键词
Human mesenchymal stem cells; Cell therapy bioprocessing; Microcarriers; Bioreactor; Regenerative medicine; Bead to bead transfer; Process intensification
资金
- Engineering and Physical Sciences Research Council via the E-TERM Landscape Fellowship programme [EP/I017801/1]
- Doctoral Training Centre in Regenerative Medicine [EP/F500491/1]
- Bioprocessing Research Industry Club (BRIC) [BB/K011066/1, BB/K01099/1]
- Pall Life Sciences
- BBSRC [BB/K010999/1] Funding Source: UKRI
- EPSRC [EP/P006485/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/K010999/1] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [EP/P006485/1] Funding Source: researchfish
Human mesenchymal stem cells (hMSCs) are a key candidate for advanced cell therapies with numerous clinical trials investigating their potential to treat acute and chronic indications. However, important translational and manufacturing challenges need to be addressed to improve our capability for scalable production of fully functional cells. In this study, we have demonstrated, both qualitatively and quantitatively, the ability of bone marrow-derived hMSCs to migrate from one microcarrier to another, and, to populate fresh microcarriers when added into suspension culture. Additionally, we have shown that compared to inoculating a culture with cells in free suspension, inoculating 10% of near-confluent microcarriers from an initial seed microcarrier culture resulted in an increase in the cell growth rate and overall cell yield and a significant reduction in the lag phase. These findings were consistent across cells from three different BM-hMSC donors and across different culture medium conditions, foetal bovine serum -supplemented medium, human platelet lysate-supplemented medium and serum-free medium. This new cells-on-beads inoculation method is an effective means of process intensification with the potential to decrease manufacturing times and potentially costs of hMSC-based therapies. (C) 2017 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据